CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞的智能控制：更安全、更有效肿瘤免疫治疗的新兴策略
英文原题：Smart control of CAR-T cells: emerging strategies for safer and more effective cancer immunotherapy.
查看英文原题
Smart control of CAR-T cells: emerging strategies for safer and more effective cancer immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）-T细胞疗法推动了癌症免疫治疗的发展，但仍受限于严重毒性、抗原逃逸以及实体瘤中疗效丧失等问题。近期智能控制系统的发展旨在通过可调控、可逆且依赖环境的机制提高CAR-T 疗法的安全性和精准性。这些包括诱导型CAR表达、逻辑门控受体以及使用药物、光或生物材料的外部控制系统的重要性。整合传感器回路和反馈环路的合成生物学方法正在为可编程免疫铺平道路，使CAR-T 活性能够实时动态调整。本研究的目的是综述能够实现CAR-T 细胞智能控制和设计活性的策略的最新进展，以用于更安全、更有效的癌症免疫治疗。它旨在总结为高精度调控CAR-T 细胞激活、持久性和细胞毒性而设计的关键分子、遗传和合成方法。
展开英文摘要原文
Chimeric Antigen Receptor (CAR)-T cell therapy has developed cancer immunotherapy but remains restricted by severe toxicities, antigen escape, and loss of efficacy in solid tumors. Recent advances in smart control systems aim to enhance the safety and precision of CAR-T therapies through tunable, reversible, and context-dependent mechanisms. These include the importance of inducible CAR expression, logic-gated receptors, and external control systems using drugs, light, or biomaterials.
Synthetic biology approaches integrating sensor circuits and feedback loops are paving the way for programmable immunity, enabling dynamic adjustment of CAR-T activity in real time. The aim of this study is to review recent advances in strategies that enable smart controlled and designed activity of CAR-T cells for safer and more effective cancer immunotherapy. It seeks to summarize key molecular, genetic, and synthetic approaches designed to regulate CAR-T cell activation, persistence, and cytotoxicity with high precision.
论文信息
- 作者
- Zhang GK、Wang HM、Zhou F
- 单位
- Department of Hematology, The 960th Hospital of The People's Liberation Army (PLA), Joint Logistics Support Force, Jinan, Shandong, China.China
- 文献类型
- 综述
- 期刊
- Frontiers in immunology2026
- 原文标识
- PubMed 41884842 · DOI 10.3389/fimmu.2026.1746673
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →